For these reasons, according to the “Statement on use of apolipoprotein E testing for Alzheimer disease”, the authors argue that genetic testing should be kept within the confines of clinical care and informed consent, in order to minimize the social and psychological damage generated by misunderstood information. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.